LISTING OF CLAIMS

Claims 1-16 (CANCELED)

- 17- (NEW) A "Reservoir" microcapsule composition for the delayed and controlled release of perindopril or a pharmaceutically acceptable salt thereof for oral administration, comprising:
- microparticles of perindopril or a pharmaceutically acceptable salt thereof, wherein the microparticles are each covered by at least one coating film, the coating film being formed from a composite material comprising:
 - at least one hydrophilic polymer A carrying groups ionised at neutral pH,
 - at least one hydrophobic compound B, representing a mass fraction (% by weight in relation to the total mass of the microcapsule) less than or equal to 40,
- wherein the microparticles have a diameter of less than 1200 microns.
- 18- (NEW) A microcapsule composition according to Claim 17, wherein the hydrophilic polymer A is selected from cellulose compounds, copolymers of methacrylic acid and a methacrylic acid ester, copolymers of methacrylic acid and an acrylic acid ester and mixtures thereof.
- 19- (NEW) A microcapsule compostion according to Claim 18, wherein the hydrophilic polymer A is a copolymer of methacrylic acid and methyl methacrylate or a copolymer of methacrylic acid and ethyl acrylate.
- **20** (NEW) A microcapsule composition according to Claim 17, wherein the hydrophobic compound B is selected from vegetable waxes, hydrogenated vegetable oils, hydrogenated triglycerides and mixtures thereof.
- 21- (NEW) A microcapsule composition according to Claim 17, wherein the hydrophobic compound B is a hydrogenated vegetable oil.

- 22- (NEW) A microcapsule composition according to Claim 17, wherein the coating film is composed of a mixture of hydrophilic polymer A and hydrophobic compound B in which the weight ratio B/A is between 0.2 and 4.
- 23- (NEW) A microcapsule composition according to Claim 17, wherein the coating film enables:
- at a pH of 1.4, a dissolution profile comprising a latent phase of a duration greater than or equal to half an hour, to be obtained,
- a release phase of perindopril to be obtained at any instant during the latent phase after transition from pH 1.4 to pH 6.8.
- **24-** (NEW) A microcapsule composition according to Claim 23, wherein the latent phase is from 1 to 8 hours.
- 25- (NEW) A microcapsule composition according to Claim 23, wherein the latent phase is from 1 to 5 hours.
- **26-** (NEW) A microcapsule composition according to Claim 17, wherein perindopril is in the form of a tert-butylamine salt.
- 27- (NEW) A microcapsule composition according to Claim 17, wherein perindopril is in the form of a arginine salt.
- **28-** (NEW) A microcapsule composition according to Claim 26, wherein perindopril or a pharmaceutically acceptable salt thereof is deposited onto a neutral core having a diameter of from 50 to 600 microns.
- **29-** (NEW) A microcapsule composition according to Claim 27, wherein perindopril or a pharmaceutically acceptable salt thereof is deposited onto a neutral core having a diameter of from 50 to 600 microns.

- 30- (NEW) A microcapsule composition according to Claim 28, wherein the neutral hydrophilic core is made of sucrose, dextrose, lactose or cellulose.
- 31- (NEW) A microcapsule composition according to Claim 29, wherein the neutral hydrophilic core is made of sucrose, dextrose, lactose or cellulose.
- **32-** (NEW) A microcapsule composition according to Claim 17, wherein the perindopril microcapsules are combined with indapamide microcapsules.
- 33- (NEW) A method of administration of an active principle to a patient in need thereof, comprising administration of the active principle in a microencapsulated form as a component of a tablet, powder, or gelatine capsule.
- **34-** (NEW) A pharmaceutical composition comprising as active principle an effective amount of a microcapsule composition according to claim 17 together with one or more pharmaceutically-acceptable excipients or vehicles.
- **35** (NEW) A pharmaceutical composition according to Claim 33 wherein the pharmaceutical composition is in the form of a tablet, powder, or gelatine capsule.
- **36-** (NEW) A pharmaceutical composition according to Claim 34 wherein the pharmaceutical composition is in the form of a gelatin capsule.
- 37- (NEW) A method for treating a living animal body, including a human, afflicted with a condition selected from arterial hypertension and heart failure, comprising the step of administering to the living animal body, including a human, an amount of a pharmaceutical composition according to Claim 33 which is effective for alleviation of the condition.